Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM
Satoshi Watanabe(Niigata University Medical and Dental Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Yuichi Takiguchi(Sanno Medical Center), Nobuyuki Yamamoto(Wakayama Medical University), Hiroshige Yoshioka(Harbin Medical University), Keisuke Tomii(Kobe City Medical Center General Hospital), Hiroshi Sakai(Hiroshima University), Seiji Niho(Dokkyo Medical University), Yukio Hosomi(Tokyo Metropolitan Komagome Hospital), M Aono(Nippon Kayaku (Japan)), Katsuyuki Hotta(Okayama University Hospital), Makoto Nishio(Japanese Foundation For Cancer Research), Shunichi Sugawara(Sendai Kousei Hospital), Hiromichi Ebi(Aichi Cancer Center), Yuichiro Ohe(National Cancer Center), Terufumi Kato(Taipei Veterans General Hospital), Mitsuhiro Takenoyama(National Hospital Organization Kyushu Cancer Center), Kazuhiko Yamada, Toshiaki Takahashi(Okayama University)
Cited by 4
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k